Science,
Journal Year:
2018,
Volume and Issue:
362(6421), P. 1416 - 1422
Published: Dec. 21, 2018
Small
molecules
spark
NK
cell
response
Immunotherapy
is
a
powerful
treatment
for
certain
cancers.
Yet
those
patients
that
do
not
respond,
simultaneous
strategies
mobilize
the
immune
system
and
directly
target
malignant
cells
may
be
more
effective.
Ruscetti
et
al.
report
combining
two
clinically
approved
cancer
drugs
promoted
surveillance
killing
of
KRAS-mutant
lung
tumors
in
mice
(see
Perspective
by
Cornen
Vivier).
The
small
molecules—a
mitogen-activated
protein
kinase
inhibitor
cyclin-dependent
4/6
inhibitor—induced
natural
killer
(NK)
recruitment
elimination
senescent
cells,
which
did
occur
when
either
agent
was
used
alone.
Science
,
this
issue
p.
1416
;
see
also
1355
Signal Transduction and Targeted Therapy,
Journal Year:
2021,
Volume and Issue:
6(1)
Published: July 12, 2021
Abstract
Cancer
development
and
its
response
to
therapy
are
regulated
by
inflammation,
which
either
promotes
or
suppresses
tumor
progression,
potentially
displaying
opposing
effects
on
therapeutic
outcomes.
Chronic
inflammation
facilitates
progression
treatment
resistance,
whereas
induction
of
acute
inflammatory
reactions
often
stimulates
the
maturation
dendritic
cells
(DCs)
antigen
presentation,
leading
anti-tumor
immune
responses.
In
addition,
multiple
signaling
pathways,
such
as
nuclear
factor
kappa
B
(NF-kB),
Janus
kinase/signal
transducers
activators
transcription
(JAK-STAT),
toll-like
receptor
(TLR)
cGAS/STING,
mitogen-activated
protein
kinase
(MAPK);
factors,
including
cytokines
(e.g.,
interleukin
(IL),
interferon
(IFN),
necrosis
(TNF)-α),
chemokines
C-C
motif
chemokine
ligands
(CCLs)
C-X-C
(CXCLs)),
growth
factors
vascular
endothelial
(VEGF),
transforming
(TGF)-β),
inflammasome;
well
metabolites
prostaglandins,
leukotrienes,
thromboxane,
specialized
proresolving
mediators
(SPM),
have
been
identified
pivotal
regulators
initiation
resolution
inflammation.
Nowadays,
local
irradiation,
recombinant
cytokines,
neutralizing
antibodies,
small-molecule
inhibitors,
DC
vaccines,
oncolytic
viruses,
TLR
agonists,
SPM
developed
specifically
modulate
in
cancer
therapy,
with
some
these
already
undergoing
clinical
trials.
Herein,
we
discuss
crosstalk
between
processes.
We
also
highlight
potential
targets
for
harnessing
cancer.
Journal of Cellular Physiology,
Journal Year:
2018,
Volume and Issue:
234(6), P. 8509 - 8521
Published: Nov. 22, 2018
CD8+
cytotoxic
T
lymphocytes
(CTLs)
are
preferred
immune
cells
for
targeting
cancer.
During
cancer
progression,
CTLs
encounter
dysfunction
and
exhaustion
due
to
immunerelated
tolerance
immunosuppression
within
the
tumor
microenvironment
(TME),
with
all
favor
adaptive
immune-resistance.
Cancer-associated
fibroblasts
(CAFs),
macrophage
type
2
(M2)
cells,
regulatory
(Tregs)
could
make
immunologic
barriers
against
CD8
+
cell-mediated
antitumor
responses.
Thus,
needed
be
primed
activated
toward
effector
in
a
process
called
immunity
cycle
making
durable
efficient
The
cell
priming
is
directed
essentially
as
corroboration
work
between
of
innate
including
dendritic
(DCs)
natural
killer
(NK)
CD4
adoptive
immunity.
Upon
activation,
infiltrate
core
or
invading
site
(so-called
infiltrated-inflamed
[I-I]
TME)
take
essential
roles
killing
cells.
Exogenous
reactivation
and/or
can
possible
using
rational
immunotherapy
strategies.
increase
ratio
costimulatory
coinhibitory
mediators
checkpoint
blockade
(ICB)
approach.
Programmed
death-1
receptor
(PD-1)-ligand
(PD-L1)
CTL-associated
antigen
4
(CTLA-4)
receptors
that
targeted
relieving
renewing
their
priming,
respectively,
thereby
eliminating
antigen-expressing
Due
diverse
relation
Tregs,
Treg
activity
dampened
increasing
number
rescuing
functional
potential
induce
immunosensitivity
Signal Transduction and Targeted Therapy,
Journal Year:
2020,
Volume and Issue:
5(1)
Published: March 20, 2020
Abstract
Colorectal
cancer
(CRC)
is
among
the
most
lethal
and
prevalent
malignancies
in
world
was
responsible
for
nearly
881,000
cancer-related
deaths
2018.
Surgery
chemotherapy
have
long
been
first
choices
patients.
However,
prognosis
of
CRC
has
never
satisfying,
especially
patients
with
metastatic
lesions.
Targeted
therapy
a
new
optional
approach
that
successfully
prolonged
overall
survival
Following
successes
anti-EGFR
(epidermal
growth
factor
receptor)
agent
cetuximab
anti-angiogenesis
bevacizumab,
agents
blocking
different
critical
pathways
as
well
immune
checkpoints
are
emerging
at
an
unprecedented
rate.
Guidelines
worldwide
currently
updating
recommended
targeted
drugs
on
basis
increasing
number
high-quality
clinical
trials.
This
review
provides
overview
existing
CRC-targeted
their
underlying
mechanisms,
discussion
limitations
future
trends.
JCI Insight,
Journal Year:
2016,
Volume and Issue:
1(17)
Published: Oct. 19, 2016
Recent
clinical
trials
have
demonstrated
a
clear
survival
advantage
in
advanced
head
and
neck
squamous
cell
carcinoma
(HNSCC)
patients
treated
with
immune
checkpoint
blockade.
These
emerging
results
reveal
that
HNSCC
is
one
of
the
most
promising
frontiers
for
immunotherapy
research.
However,
further
progress
immuno-oncology
will
require
detailed
understanding
infiltrative
landscape
found
these
tumors.
We
leveraged
transcriptome
data
from
280
tumors
profiled
by
The
Cancer
Genome
Atlas
(TCGA)
to
comprehensively
characterize
order
develop
rationale
immunotherapeutic
strategies
guide
investigation.
find
both
HPV
